Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PPBT 
Purple Biotech (PPBT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: PPBT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $34
1 Year Target Price $34
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -73.65% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.69M USD | Price to earnings Ratio - | 1Y Target Price 34 |
Price to earnings Ratio - | 1Y Target Price 34 | ||
Volume (30-day avg) 1 | Beta -0.74 | 52 Weeks Range 0.53 - 8.40 | Updated Date 11/6/2025 |
52 Weeks Range 0.53 - 8.40 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -45.9 |
Earnings Date
Report Date 2025-11-13 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -10.27% | Return on Equity (TTM) -8.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 171927 | Price to Sales(TTM) 58.08 |
Enterprise Value 171927 | Price to Sales(TTM) 58.08 | ||
Enterprise Value to Revenue 33.08 | Enterprise Value to EBITDA -0.15 | Shares Outstanding 9030449 | Shares Floating 508630430 |
Shares Outstanding 9030449 | Shares Floating 508630430 | ||
Percent Insiders 6.51 | Percent Institutions 3.82 |
Upturn AI SWOT
Purple Biotech
Company Overview
History and Background
Purple Biotech Ltd. (formerly Kitov Pharma) is a biopharmaceutical company focused on developing and commercializing therapies for cancer. Founded in 2010, it has undergone strategic shifts, including the acquisition of certain assets from Immune Pharmaceuticals, to concentrate on oncology. Recent efforts focus on its clinical-stage oncology assets.
Core Business Areas
- CM24: A monoclonal antibody targeting CEACAM5, currently in clinical development for various solid tumors. Focus is on overcoming resistance to current therapies.
- NT219: A novel small molecule designed to inhibit IRS1/2, which is also in clinical trials for solid tumors. This is supposed to deal with drug resistance for solid tumors.
Leadership and Structure
Purple Biotech's leadership team consists of experienced professionals in the pharmaceutical and biotech industries. The company has a board of directors and an executive management team responsible for strategic direction and operational execution.
Top Products and Market Share
Key Offerings
- CM24: A monoclonal antibody targeting CEACAM5, in clinical development. Market share is currently zero, as it's pre-commercialization. Competitors include companies developing other CEACAM5 inhibitors or alternative cancer therapies, such as those employing CAR-T cell therapy or other targeted antibodies. No users or revenue at this stage.
- NT219: A novel small molecule inhibiting IRS1/2, in clinical development. Market share is currently zero. Competitors include companies developing other IRS1/2 inhibitors or therapies targeting similar resistance mechanisms. No users or revenue at this stage.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by an aging population and advancements in cancer diagnostics and treatment. It is characterized by intense competition and high R&D costs.
Positioning
Purple Biotech is positioning itself in the oncology market by developing therapies that target resistance mechanisms in cancer. This approach aims to address unmet needs in patients who have failed to respond to existing treatments.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars annually. Purple Biotech is targeting specific niches within this market, particularly those related to drug resistance in solid tumors. The TAM for these niches is significant, and Purple Biotech's position depends on the clinical success and commercialization of its pipeline.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets (CEACAM5 and IRS1/2)
- Clinical-stage assets
- Experienced management team
Weaknesses
- Limited financial resources
- High R&D risk
- Dependence on clinical trial success
Opportunities
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Expansion into new indications
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- LLY
- MRK
- BMY
- AZN
Competitive Landscape
Purple Biotech faces intense competition from established pharmaceutical companies with greater resources. Its competitive advantage lies in its novel therapeutic targets and potential to address unmet needs in cancer treatment.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by pipeline advancement and securing funding.
Future Projections: Future growth is contingent on the success of clinical trials and potential commercialization of CM24 and NT219. Analyst projections vary widely, reflecting the inherent risk in biotechnology.
Recent Initiatives: Recent initiatives likely include advancing clinical trials for CM24 and NT219, seeking partnerships, and potentially exploring new indications for its assets.
Summary
Purple Biotech is a clinical-stage biotech company with novel therapeutic targets that could be promising in the oncology sector, but its limited resources and reliance on successful clinical trials create substantial risk. The company's future hinges on the success of CM24 and NT219, and their ability to forge partnerships with larger pharmaceutical companies. Key aspects to watch are trial outcomes, funding activities, and shifts in the competitive landscape. Its success relies on successfully navigating the highly competitive landscape of oncology drug development.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Purple Biotech's website
- SEC filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is for informational purposes only and should not be construed as a recommendation to buy or sell securities. The biotech industry is highly volatile, and investments involve significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Purple Biotech
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2015-11-20 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 9 | Website https://purple-biotech.com |
Full time employees 9 | Website https://purple-biotech.com | ||
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.